Uplifting News

This is an automated archive made by the Lemmit Bot.

The original was posted on /r/upliftingnews by /u/No-Zucchini3759 on 2024-09-19 18:59:41+00:00.

Here is a link to the publication of the research:

“Hereditary hemorrhagic telangiectasia (HHT), the world's second-most-common inherited bleeding disorder, affects approximately 1-in-5,000 people and can have life-threatening complications, but there are currently no U.S. FDA-approved drugs to treat HHT.”

“The results of our trial demonstrate the clear safety and efficacy of pomalidomide to treat bleeding in HHT, giving these patients a much-needed effective treatment option," said first author Hanny Al-Samkari, MD, the Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General Hospital.